Muscular Atrophy Clinical Trials

73 recruitingLast updated: June 20, 2026

There are 73 actively recruiting muscular atrophy clinical trials across 36 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include Norfolk, Virginia, United States, New York, New York, United States, Palo Alto, California, United States. Updated daily from ClinicalTrials.gov.


Muscular Atrophy Trials at a Glance

73 actively recruiting trials for muscular atrophy are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Norfolk, New York, and Palo Alto. Lead sponsors running muscular atrophy studies include Biogen, Assistance Publique - Hôpitaux de Paris, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Browse muscular atrophy trials by phase

Treatments under study

About Muscular Atrophy Clinical Trials

Looking for clinical trials for Muscular Atrophy? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscular Atrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscular Atrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 73 trials

Recruiting

Clinical Procedures to Support Research in ALS

Amyotrophic Lateral SclerosisPrimary Lateral SclerosisProgressive Muscular Atrophy+1 more
University of Miami1,200 enrolled11 locationsNCT03489278
Recruiting
Not Applicable

VRehab-SMA Phase 1.2

Spinal Muscular Atrophy (SMA)
University of Oxford12 enrolled1 locationNCT07578454
Recruiting
Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Muscular Atrophy, Spinal
Biogen30 enrolled4 locationsNCT07221669
Recruiting
Phase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Muscular Atrophy, Spinal
Hoffmann-La Roche28 enrolled19 locationsNCT05861999
Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA)
argenx60 enrolled17 locationsNCT07287982
Recruiting
Not Applicable

Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers

Myotonic DystrophyMuscular DystrophyCharcot-Marie-Tooth+1 more
Institut de Myologie, France30 enrolled1 locationNCT07321977
Recruiting

ALS/MND Natural History Study Data Repository

ALSKennedy DiseasePLS+3 more
Massachusetts General Hospital5,000 enrolled18 locationsNCT05966038
Recruiting

Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

Spinal Muscular Atrophy
Columbia University45 enrolled1 locationNCT06955897
Recruiting

An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)

Spinal Muscular Atrophy (SMA)
University of Oxford90 enrolled1 locationNCT07543003
Recruiting
Not Applicable

Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy

Infantile Spinal Muscular AtrophySpinal AmyotrophyJuvenile Spinal Muscular Atrophy
Centre Hospitalier Universitaire de Saint Etienne80 enrolled4 locationsNCT06562283
Recruiting
Phase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Muscular Atrophy, Spinal
Hoffmann-La Roche28 enrolled16 locationsNCT05861986
Recruiting
Phase 2

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

Muscular Atrophy, Spinal
Hoffmann-La Roche10 enrolled13 locationsNCT05808764
Recruiting
Phase 2

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Spinal Muscular AtrophySMASpinal Muscular Atrophy Type 3+3 more
Scholar Rock, Inc.52 enrolled25 locationsNCT07047144
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting
Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Spinal Muscular Atrophy
Biogen90 enrolled1 locationNCT07444476
Recruiting

Invasive Home Ventilation in Denmark

Spinal Cord Injuries (SCI)Neuromuscular Diseases (NMD)MSA - Multiple System Atrophy+5 more
Rigshospitalet, Denmark450 enrolled1 locationNCT07467187
Recruiting
Not Applicable

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Spinal Muscular AtrophyScoliosisSpine Deformity
Alcyone Therapeutics, Inc90 enrolled21 locationsNCT05866419
Recruiting

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

Amyotrophic Lateral SclerosisPrimary Lateral SclerosisProgressive Muscular Atrophy+1 more
University of Alberta150 enrolled4 locationsNCT05204017
Recruiting

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Duchenne Muscular Dystrophy (DMD)Spinal Muscular Atrophy Type 3
Columbia University106 enrolled3 locationsNCT06839469
Recruiting
Not Applicable

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

Spinal Cord Injuries (SCI)Amyotrophic Lateral Sclerosis(ALS)Muscular Dystrophies+6 more
Johns Hopkins University5 enrolled1 locationNCT07521930